
    
      This Phase 2a study was conducted in 2 parts. Part A was a randomized, single-dose,
      double-blind, placebo- and active-controlled, 3-way crossover phase during which participants
      were administered study medication in the clinical facility. Part B was a 14-day, randomized,
      double-blind, placebo-controlled, parallel-group, multiple-dose phase in which participants
      self-administered study medication at home.
    
  